The concept of combining chemotherapeutic agents to increase cytotoxic efficacy has
evolved greatly over the past several years. The rationale for combination chemotherapy …

PURPOSE AND METHODS: For more than three decades, the therapeutic options for
patients with advanced colorectal cancer have almost exclusively been based on …

A systematic review of chemotherapy trials in several tumour types was performed by The
Swedish Council of Technology Assessment in Health Care (SBU). The procedures for the …

Chemotherapy-induced diarrhea (cid) is a common side effect of cancer treatment and can
cause significant morbidity and mortality. Diarrhea is frequently severe enough to require a …

We evaluated irinotecan (CPT-11) together with 5-fluorouracil (5-FU) for improved cell
growth inhibition with respect to that by either agent alone in the human colon carcinoma …

PURPOSE: To determine the maximum-tolerated dose (MTD) and recommended dose of
irinotecan (CPT-11) in combination with fluorouracil (5-FU) and leucovorin (LV), using a …

Background Colorectal cancer (CRC) is the third major cause of cancer related deaths in the
world. 5-fluorouracil (5-FU) is widely used for the treatment of colorectal cancer but as a …

Options for first‐line chemotherapy in patients with metastatic colorectal carcinoma have
broadened considerably with the introduction of irinotecan and oxaliplatin. Furthermore, the …

The anticancer agents fluorouracil, raltitrexed, irinotecan and oxaliplatin show limited
efficacy in the treatment of colorectal cancer and may be associated with substantial toxicity …

The concept of combining chemotherapeutic agents to increase the cytotoxic efficacy has
evolved greatly over the past several years. In the past, the rationale for combination …